View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. Emisphere Technologies
13 December 2019

Emisphere Development Update

Novo Nordisk has announced the Federal Food and Drug Administration (FDA) approved Rybelsus, a semaglutide tablet, to treat adults with type 2 diabetes.

Oral semaglutide, a once-daily oral formulation of the long-acting GLP-1 analogue for the treatment of Type 2 diabetes, utilises Emisphere Technologies, Inc.’s (“Emisphere” or the “Company”) (OTCBB:EMIS) proprietary Eligen® SNAC Carrier Technology. A copy of Novo Nordisk’s announcement can be found on our website. Please fill out the enquiry form attached to this page for more details.

About Emisphere

Emisphere is a drug delivery company that utilizes its proprietary Eligen® Technology to develop new oral formulations of therapeutic agents. Emisphere is currently partners with global pharmaceutical companies for the development of new orally delivered therapeutics.

This press release may contain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934.

Such statements include, but are not limited to, any statements relating to the Company’s development activities and any other statements that are not historical facts. Such statements involve risks and uncertainties, including, but not limited to, those risks and uncertainties relating to the Company’s business development activities.

Such statements are based on management’s current expectations, but actual results may differ materially due to various factors, including, but not limited to, the sufficiency of Emisphere’s cash position, the success of our and our partner’s development and commercialization efforts, and our ability to successfully partner our Eligen® Technology.

Emisphere's Eligen® Technology binds a delivery agent with a therapeutic compound without alternation. This process occurs when both agent and compound are in close proximity.
Originally published by Elsevier Journals on 24 May 2011, this white paper outlines an open-label, randomised, single-dose, parallel-group study of the pharmacokinetics of oral cyanocobalamin...
NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Pharmaceutical Technology